AV
ARCH Venture Partners XII, LLC
内部人交易记录
其他基于 2 个已确定 T+90 收益的买入信号。收益基准：公布次日的收盘价。
Explore the full record of transactions filed by ARCH Venture Partners XII, LLC. Insider active across 4 companies, notably Neumora Therapeutics, Inc.. Cumulatively, 16 disclosures have been logged. Split: 11 buys · 0 sell. Total volume traded: €34.8m. Activity tracked since 22 September 2023. The latest transaction was disclosed on 27 October 2025 (Acquisition). Regulator: SEC (Form 4). The full history is accessible without signup.
Companies and markets linked to ARCH Venture Partners XII, LLC
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报16 总计
18,503,128 股Common StockSEC:0001012975-25-000791:0
1,915,700 股@ US$2.6158.3% 占其流量Common StockSEC:0001012975-25-000680:0
3,030,300 股@ US$3.3032.0% 占其流量Common StockSEC:0001062993-25-013461:0
16,006,949 股Common StockSEC:0000950170-25-012579:0
3,728,738 股0Common StockSEC:0000950170-24-071543:0
3,200,000 股@ US$6.25100.0% 占其流量Common StockSEC:0001062993-24-003739:0
703,061 股Common StockSEC:0001062993-23-022481:0
1,176,593 股Common StockSEC:0001062993-23-022481:1
31,653 股@ US$11.7511.3% 占其流量Common StockSEC:0001062993-23-020933:0
69,127 股@ US$10.7822.7% 占其流量Common StockSEC:0001062993-23-020712:0
43,082 股@ US$11.5515.1% 占其流量Common StockSEC:0001062993-23-020279:1
30,192 股@ US$11.5010.5% 占其流量Common StockSEC:0001062993-23-020279:2
22,420 股@ US$11.387.8% 占其流量Common StockSEC:0001062993-23-020279:0
16,841 股@ US$13.0620.8% 占其流量Common StockSEC:0001062993-23-018632:0
34,000 股@ US$11.7337.6% 占其流量Common StockSEC:0001062993-23-018547:0
40,000 股@ US$11.1441.6% 占其流量Common StockSEC:0001062993-23-018469:0
About ARCH Venture Partners XII, LLC
ARCH Venture Partners XII, LLC has filed 16 filings in total. Across the 16 recent filings available, all transactions are acquisitions, with buy volume of EUR 34763745 between 2023-09-25 and 2025-11-14. The companies involved are Neumora Therapeutics, Inc., Metsera, Inc., where the entity is a Director, Prime Medicine, Inc., and Rapport Therapeutics, Inc.